Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 12, 2012 - Issue 2
Submit an article Journal homepage
234
Views
18
CrossRef citations to date
0
Altmetric
Drug Profile

IPX066: a novel carbidopa–levodopa extended-release formulation

Robert A Hauser University of South Florida Parkinson’s Disease and Movement Disorders Center, NPF Center of Excellence, Byrd Institute, 4001 E. Fletcher Ave, 6th Floor, Tampa, FL 33613, USA. [email protected]
Pages 133-140 | Published online: 09 Jan 2014

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Nataša Dragašević-Mišković, Igor Petrović, Iva Stanković & Vladimir S. Kostić. (2019) Chemical management of levodopa-induced dyskinesia in Parkinson’s disease patients. Expert Opinion on Pharmacotherapy 20:2, pages 219-230.
Read now
Livia Dézsi & László Vécsei. (2014) Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs. Expert Opinion on Drug Metabolism & Toxicology 10:3, pages 409-424.
Read now
Brenton A Wright & Cheryl H Waters. (2013) Continuous dopaminergic delivery to minimize motor complications in Parkinson’s disease. Expert Review of Neurotherapeutics 13:6, pages 719-729.
Read now

Articles from other publishers (15)

Mohammad Al Majali, Michael Sunnaa & Pratap Chand. (2021) Emerging Pharmacotherapies for Motor Symptoms in Parkinson’s Disease. Journal of Geriatric Psychiatry and Neurology 34:4, pages 263-273.
Crossref
Jason Margolesky & Carlos Singer. (2017) Extended-release oral capsule of carbidopa–levodopa in Parkinson disease. Therapeutic Advances in Neurological Disorders 11, pages 175628561773772.
Crossref
Maria João Forjaz, Carmen Rodriguez-Blazquez & Pablo Martinez-Martin. 2017. Movement Disorders Curricula. Movement Disorders Curricula 165 180 .
Cicely Kerr, Emily J. Lloyd, Charlotte E. Kosmas, Helen T. Smith, James A. Cooper, Karissa Johnston, Emma McIntosh & Andrew J. Lloyd. (2015) Health-related quality of life in Parkinson’s: impact of ‘off’ time and stated treatment preferences. Quality of Life Research 25:6, pages 1505-1515.
Crossref
Sarah L. Greig & Kate McKeage. (2015) Carbidopa/Levodopa ER Capsules (Rytary®, Numient™): A Review in Parkinson’s Disease. CNS Drugs 30:1, pages 79-90.
Crossref
Pablo Martinez-Martin, Carmen Rodriguez-Blazquez, Maria João Forjaz & Monica M. Kurtis. (2015) Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson’s Disease. CNS Drugs 29:5, pages 397-413.
Crossref
Cheryl H. Waters, Paul Nausieda, Lyudmila Dzyak, Joerg Spiegel, Monika Rudzinska, Dee E. Silver, Elena S. Tsurkalenko, Sherron Kell, Ann Hsu, Sarita Khanna & Suneel Gupta. (2015) Long-Term Treatment with Extended-Release Carbidopa–Levodopa (IPX066) in Early and Advanced Parkinson’s Disease: A 9-Month Open-Label Extension Trial. CNS Drugs 29:4, pages 341-350.
Crossref
Fabrizio Stocchi, Ann Hsu, Sarita Khanna, Aaron Ellenbogen, Andreas Mahler, Grace Liang, Ulrich Dillmann, Robert Rubens, Sherron Kell & Suneel Gupta. (2014) Comparison of IPX066 with carbidopa–levodopa plus entacapone in advanced PD patients. Parkinsonism & Related Disorders 20:12, pages 1335-1340.
Crossref
Fabrizio Stocchi. (2013) Therapy for Parkinson’s Disease: What is in the Pipeline?. Neurotherapeutics 11:1, pages 24-33.
Crossref
Joseph JankovicJoseph Jankovic. 2013. Parkinson’s Disease: Medical and Surgical Treatment. Parkinson’s Disease: Medical and Surgical Treatment 139 148 .
K. Ray Chaudhuri, Alexandra Rizos & Kapil D. Sethi. (2013) Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery?. Journal of Neural Transmission 120:9, pages 1305-1320.
Crossref
Maria Papathanou, Rika van der Laan, Peter Jenner, Sarah Rose & Andrew C. McCreary. (2013) Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats. Movement Disorders 28:8, pages 1072-1079.
Crossref
Talene A Yacoubian. (2013) IPX066: a new intermediate- and extended-release carbidopa–levodopa formulation. Neurodegenerative Disease Management 3:2, pages 123-131.
Crossref
Fabienne Sprenger & Werner Poewe. (2013) Management of Motor and Non-Motor Symptoms in Parkinson’s Disease. CNS Drugs 27:4, pages 259-272.
Crossref
Manuela Pilleri, Konstantinos Koutsikos & Angelo Antonini. (2012) Is there room for new non-dopaminergic treatments in Parkinson’s disease?. Journal of Neural Transmission 120:2, pages 349-352.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.